Premium
Additional value of the ratio of serum total testosterone to total prostate‐specific antigen in the diagnosis of prostate cancer in a Chinese population
Author(s) -
Xu L.,
Hu X.,
Zhu Y.,
Lu J.,
Xu Y.,
Wang G.,
Guo J.
Publication year - 2018
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.12872
Subject(s) - urology , medicine , prostate specific antigen , prostate cancer , testosterone (patch) , hyperplasia , prostate , gynecology , population , cancer , gastroenterology , environmental health
Summary We investigated whether serum testosterone and testosterone/prostate‐specific antigen ratio (T/ PSA ) might be prostate cancer ( PC a) biomarkers. We retrospectively reviewed 92 patients with benign prostatic hyperplasia ( BPH ) and 164 patients with PC a treated at Zhongshan Hospital, China (April 2012 to November 2013). The BPH and PC a groups had similar serum total testosterone (median, 15.8 versus 16.3 nmol/L).Compared with the BPH group, the PC a group had higher PSA (16.8 versus 5.1 ng/ml) and lower free/total PSA (9.5% versus 19.3%) and T/ PSA (1.37 versus 4.69) (all p < .001).Patients with PC a and PSA ≤20 ng/ml had higher testosterone (17.5 versus 12.9 ng/ml; p = .002) and T/ PSA (2.24 versus 0.29; p < .001) than those with PSA >20 ng/ml. Patients with PC a and Gleason score ≤7 had higher testosterone (18.3 versus 14.1 ng/ml; p = .023) and T/ PSA (1.93 versus 0.72; p < .001) than those with Gleason score >7. In patients with PSA ≤20 ng/ml, T/ PSA was higher in those with BPH than in those with PC a (4.69 versus 2.24; p < .001). ROC curve analysis yielded an AUC of 0.712; for the optimal cut‐off of 4.43, specificity and sensitivity were 52% and 97% respectively. T/ PSA may improve the accuracy of PC a diagnosis in patients with a PSA level ≤20 ng/ml.